Cancer misdiagnosis and mistreatment in India present significant challenges, not only for patients and their families but also for society and the economy as a whole. These issues lead to substantial negative externalities, including a deadweight loss caused by the misallocation of vital healthcare resources. However, advancements in genomic diagnosis and sequencing offer promising potential for improving the accuracy of cancer detection and treatment. This paper explores the field of genomic medicine and evaluates its effectiveness in India, with a focus on how advancements in the country's biotechnology industry can help reduce the socio-economic costs currently borne by the nation.
No takes yet. Share an insight, caveat, or question.
Shyla Sama (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: